H.C. Wainwright raised the firm’s price target on SpringWorks Therapeutics to $74 from $73 and keeps an Overweight rating on the shares following the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics submits rolling NDA to FDA for mirdametinib
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- 3 Best Stocks to Buy Now, 3/1/2024, According to Top Analysts
- SpringWorks Therapeutics announces EMA validaion for nirogacestat MAA
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors